Seung Bum Park

Bio: Seung Bum Park is an academic researcher from Seoul National University. The author has contributed to research in topics: Medicine & Fluorophore. The author has an hindex of 43, co-authored 213 publications receiving 6983 citations. Previous affiliations of Seung Bum Park include Howard Hughes Medical Institute & UPRRP College of Natural Sciences.

Specific Targeting, Cell Sorting, and Bioimaging with Smart Magnetic Silica Core–Shell Nanomaterials

Abstract: Magnetic nanoparticles (MNPs) have been used in various areas, such as in the manufacture of bearings, seals, lubricants, heat carriers, and in printing, recording, and polishing media. [1] One of the rapidlydeveloping research subjects involving MNPs is their application in biological systems, including their application in magnetic resonance imaging (MRI), targeted drug delivery, rapid biological separation, biosensors, and magnetic hyperthermia therapy. [2] The exploration of the interaction between nanostructured materials and living systems is of fundamental and practical interest, and it opens new doors to novel interdisciplinaryresearch field, “nanobioscience”. MNPs exhibited great potential for in vitro and in vivo biomedical application, [3] and the biodistribution of MNPs is stronglyinfluenced bytheir size, charge, and surface chemistry. [4] Recentlypublished reports indicate that magnetic nanoparticles (or microparticles), Fe3O4, conjugated with various targeting molecules or antibodies, can be used to target specific cells in vitro. [5] However, the noncovalent surface modification of nanoparticles

Privileged Structures: Efficient Chemical “Navigators” toward Unexplored Biologically Relevant Chemical Spaces

Abstract: In the search for new therapeutic agents for currently incurable diseases, attention has turned to traditionally “undruggable” targets, and collections of drug-like small molecules with high diversity and quality have become a prerequisite for new breakthroughs. To generate such collections, the diversity-oriented synthesis (DOS) strategy was developed, which aims to populate new chemical space with drug-like compounds containing a high degree of molecular diversity. The resulting DOS-derived libraries have been of great value for the discovery of various bioactive small molecules and therapeutic agents, and thus DOS has emerged as an essential tool in chemical biology and drug discovery. However, the key challenge has become how to design and synthesize drug-like small-molecule libraries with improved biological relevancy as well as maximum molecular diversity. This Perspective presents the development of privileged substructure-based DOS (pDOS), an efficient strategy for the construction of polyheterocy...

疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A

Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1（PfPMP1）与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用，在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员，通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

Aggregation-Induced Emission: Together We Shine, United We Soar!

Abstract: Ju Mei,†,‡,∥ Nelson L. C. Leung,†,‡,∥ Ryan T. K. Kwok,†,‡ Jacky W. Y. Lam,†,‡ and Ben Zhong Tang*,†,‡,§ †HKUST-Shenzhen Research Institute, Hi-Tech Park, Nanshan, Shenzhen 518057, China ‡Department of Chemistry, HKUST Jockey Club Institute for Advanced Study, Institute of Molecular Functional Materials, Division of Biomedical Engineering, State Key Laboratory of Molecular Neuroscience, Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China Guangdong Innovative Research Team, SCUT-HKUST Joint Research Laboratory, State Key Laboratory of Luminescent Materials and Devices, South China University of Technology, Guangzhou 510640, China

Nanoparticle therapeutics: an emerging treatment modality for cancer

Abstract: Nanoparticles — particles in the size range 1–100 nm — are emerging as a class of therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumours and active cellular uptake. Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While large numbers of preclinical studies have been published, the emphasis here is placed on preclinical and clinical studies that are likely to affect clinical investigations and their implications for advancing the treatment of patients with cancer.